Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands
Auto-generated profile, based on publicly available information
Fabiënne van Puijfelik
Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands
Multiple sclerosis (MS) is a common and devastating chronic inflammatory disease of the CNS. CD4+ T cells are assumed to be the first to cross the blood–central nervous system (CNS) barrier and trigger local inflammation. Here, we explored how pathogenicity‐associated effector programs define CD4+ T cell subsets with brain‐homing ability in MS. Runx3‐ and Eomes‐, but not T‐bet‐expressing CD4+ memory cells were diminished in the blood of MS patients. This decline reversed following natalizumab treatment and was supported by a Runx3+Eomes+T‐bet− enrichment in cerebrospinal fluid samples of treatment‐naïve MS patients. This transcription factor profile was associated with high granzyme K (GZMK) and CCR5 levels and was most prominent in Th17.1 cells (CCR6+CXCR3+CCR4−/dim). Previously published CD28− CD4 T cells were characterized by a Runx3+Eomes−T‐bet+ phenotype that coincided with intermediate CCR5 and a higher granzyme B (GZMB) and perforin expression, indicating the presence of two separate subsets. Under steady‐state conditions, granzyme Khigh Th17.1 cells spontaneously passed the blood–brain barrier in vitro. This was only found for other subsets including CD28− cells when using inflamed barriers. Altogether, CD4+ T cells contain small fractions with separate pathogenic features, of which Th17.1 seems to breach the blood–brain barrier as a possible early event in MS.
The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary progressive multiple sclerosis. CD20 is a prototypical B cell marker, however subpopulations of CD4+ and CD8+ T cells in peripheral blood and cerebrospinal fluid (CSF) also express low levels of CD20 (CD20dim). Therefore, direct targeting and depletion of these CD20dim T-cell-subpopulations may contribute to the therapeutic effect of ocrelizumab. The aim of this observational cohort study was to compare CD20+ B cell and CD20dim T cell distributions between peripheral blood and CSF of ocrelizumab-treated or untreated people with primary progressive multiple sclerosis. Ocrelizumab treatment was associated with depletion of circulating B cells and CD20dim CD4+ and CD20dim CD8+ T cells (P < 0.0001, P = 0.0016, and P = 0.0008, respectively), but in CSF only with lower proportions of B cells and CD20dim memory CD4+ T cells (P < 0.0001 and P = 0.0043, respectively). The proportional prevalence of CSF CD20dim memory CD8+ T cells was not significantly reduced (P = 0.1333). Only in CSF, the proportions of CD20dim cells within CD4+ and not CD8+ T cells positive for CCR5, CCR6 and CXCR3 were reduced in ocrelizumab-treated participants. The proportion of CD20dim CD4+ T cells and abundance of CD4+ relative to CD8+ T cells in CSF correlated positively with age (R = 0.6799, P = 0.0150) and Age Related Multiple Sclerosis Severity Score (R = 0.8087, P = 0.0014), respectively. We conclude that, in contrast to CSF CD20dim CD8+ T cells, B cells and CD20dim CD4+ T cells are reduced in CSF of people with primary progressive multiple sclerosis with an ocrelizumab-associated depletion of circulating B cells and CD20dim T cells. Therefore, these cells are likely to contribute to the therapeutic effects of ocrelizumab in people with primary progressive multiple sclerosis.
Decades of immunological and genetic studies highlight CD4+ T cells as initiators of central nervous system (CNS) pathology in individuals who develop multiple sclerosis (MS). A low-frequency CD4+ T-cell population termed T helper 17.1 (Th17.1) has been argued to play a central role during MS onset due to differences in abundance, yet little is known about their functional heterogeneity and distinctive mode of action in MS. Features that distinguished Th17.1 from Th17 and Th1 cells in the blood were explored using spectral flow cytometry. We focused on the brain-homing properties of Th17.1 in MS by analysing paired blood and cerebrospinal fluid (CSF) as well as blood before and after natalizumab treatment. Identified Th17.1 effector signatures were further analysed using purified subsets for single-cell transcriptomics and corresponding in vitro stimulation assays. Our screens reveal an CCR5high Th17.1 cluster that is enriched in CSF, but also selectively reduced in post-versus pre-natalizumab blood samples from people with MS. The phenotypical and transcriptional signature of this Th17.1 cluster matched and pointed to a highly receptive and pre-cytotoxic state. Indeed, particularly CCR5high Th17.1 cells upregulated cytolytic proteins by strongly responding to IL-12, while secretion of these proteins was only found when adding both IL-12 and IL-18 in vitro. We show that low-frequency, circulating Th17.1 cells harbour a unique MS-associated CCR5high cluster with enhanced cytotoxic and CNS-infiltrating potential. This CD4+ cytotoxic T-cell precursor could be a promising target for future research aimed at monitoring disease-relevant immune perturbations for precision medicine in MS. 10.13039/501100001826 ZonMw (09150171910036), 10.13039/501100003000 Stichting MS Research (19–1075 MS, 23–490 g MS), European Union’s Horizon Europe Research and Innovation Actions (101137235; BEHIND-MS) and the 10.13039/501100007352 Swiss State Secretariat for Education, Research and Innovation (SERI), Erasmus MC Foundation (10502/02).